Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in TNF-Experienced Psoriatic Arthritis
NCT02349295Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2014
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of ixekizumab in psoriatic arthritis (PsA), sponsored by Eli Lilly and Company. Started Dec 2014; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02349295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349295.